Bariatric surgery modulates plasma levels of antibodies against angiotensin II type 1 and endothelin 1 type A receptor in severe obesity.

Autor: Di Vincenzo A; Internal Medicine 3, Department of Medicine, University-Hospital of Padova, Padua, Italy. angelo.divincenzo@unipd.it.; Endocrine-Metabolic Laboratory, Department of Medicine, University-Hospital of Padova, Padua, Italy. angelo.divincenzo@unipd.it., Granzotto M; Endocrine-Metabolic Laboratory, Department of Medicine, University-Hospital of Padova, Padua, Italy., Trevellin E; Endocrine-Metabolic Laboratory, Department of Medicine, University-Hospital of Padova, Padua, Italy., Purificati C; Internal Medicine 3, Department of Medicine, University-Hospital of Padova, Padua, Italy., Vecchiato M; Sports and Exercise Medicine Division, Department of Medicine, University-Hospital of Padova, Padua, Italy., Foletto M; Week Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University-Hospital of Padova, Padua, Italy., Pesavento M; Internal Medicine 3, Department of Medicine, University-Hospital of Padova, Padua, Italy., Vettor R; Internal Medicine 3, Department of Medicine, University-Hospital of Padova, Padua, Italy.; Endocrine-Metabolic Laboratory, Department of Medicine, University-Hospital of Padova, Padua, Italy., Rossato M; Internal Medicine 3, Department of Medicine, University-Hospital of Padova, Padua, Italy.; Endocrine-Metabolic Laboratory, Department of Medicine, University-Hospital of Padova, Padua, Italy.
Jazyk: angličtina
Zdroj: Journal of endocrinological investigation [J Endocrinol Invest] 2024 Jun 20. Date of Electronic Publication: 2024 Jun 20.
DOI: 10.1007/s40618-024-02412-4
Abstrakt: Purpose: The contribution of endothelial-targeted autoantibodies against the angiotensin II type 1 receptor (anti-AT1R) and the anti-endothelin 1 type A receptor (anti-ETAR1) has been proposed in the development of cardiovascular diseases. However, no data have been reported yet in obesity. In this observational study we evaluated the relationship between anthropometric and metabolic parameters and anti-AT1R and anti-ETAR1 concentrations in a cohort of patients with severe obesity and associated comorbidities undergoing bariatric surgery.
Methods: Clinical evaluation and metabolic assessment were performed in 36 subjects referring to our Center for the Study and Integrated Treatment of Obesity at the University Hospital of Padova. Circulating inflammatory adipocytokines and the endothelial dysfunction marker asymmetric dimethylarginine (ADMA) were evaluated; plasma levels of anti-AT1R and anti-ETAR1 were also determined. 10 normal-weight subjects were considered as a control group. 29 patients out of 36 were re-evaluated after surgery.
Results: With respect to normal-weight controls patients showed significantly higher plasma levels of anti-AT1R (28 ± 20.4 vs 13.5 ± 2.8 U/mL, p < 0.005) and ADMA (0.8 ± 0.1 vs 0.54 ± 0.08 uM/L, p < 0.0001) but not anti-ETAR1 (14.2 ± 1.3 vs 13.3 ± 2 U/mL, p = 0.1). Anti-AT1R concentration showed an increasing trend with the worsening of glycemic status, while the presence of arterial hypertension among the patients did not affect autoantibodies levels. One year after surgery, a significant improvement in body weight and metabolic and inflammatory parameters was observed, along with a significant reduction of anti-AT1R (28.1 ± 20.4 U/mL vs 22.6 ± 16 U/mL, p < 0.05) and anti-ETAR1 (14.2 ± 1.3 U/L vs 13 ± 1.6 U/L, p < 0.01).
Conclusions: Subjects with obesity present higher plasma levels of anti-AT1R which are more related to glycemic profile than blood pressure levels, and are reduced by bariatric surgery. Considering the detrimental effects of these autoantibodies on vascular health, they should be assessed as potential biomarkers in obesity and metabolic diseases.
(© 2024. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).)
Databáze: MEDLINE
Externí odkaz: